Ei.Ventures And Mycotopia To Merge Into New Psychedelic Mushroom Company
Two companies in the psychedelics space have signed a definitive agreement to merge.
Awakn’s Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research
Awakn Life Sciences (OTCQB: AWKNF) has announced the successful completion of the first ketamine study for a varied set of behavioral addictions.
MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance
MindMed Inc. (NASDAQ: MNMD) reported favorable results for one of its proprietary compounds.
Novamind To Offer Ketamine Treatment To Frontline Workers Who Suffer Pandemic-Related Distress
After a period of clinical pilot, Novamind Inc. (OTCQB: NVMDF) will offer Frontline KAP, group-based ketamine-assisted psychotherapy or KAP, for frontline workers, at some of its clinics.
Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics
It’s been a long and arduous road for Revive Therapeutics Ltd. (OTC: RVVTF) regarding their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.
Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End
Psychedelics biotech company Clearmind Medicine Inc.
Psychedelics Atai Life Sciences: Optimizing Drug Development By Avoiding Big Pharma’s Past Missteps
In the early days of the psychedelics industry, financial reports mean very little. Unless a company wildly misses its operating spending budget and hemorrhages cash by more than expected, the report is basically a synopsis of a given company’s highlights and milestones over the previous quarter.
Aurora Sky Is No More, Stablecoins Melt Down and SAFE Banking Receives Another Boost
In this week’s Trade To Black Podcast, TDR Founder Shadd Dales, lead financial writer Benjamin A. Smith and millennial entrepreneur Anthony Varrell talk macro market, crypto, the dangers of algorithmic stablecoins, Aurora Sky shuttering its doors, U.S. cannabis and psychedelics.
Psyched: Compass, Atai And MindMed Release Q1 Earnings, Phase 3 MDMA Trial Closer To Completion, Enveric Splits Into Two Companies
The psychedelics space got a new glimpse at the financials of some of its heavy hitters with the release of earnings reports for the first quarter of 2022.
Psychedelics Retreats Coming To Canada Could Soon Offer Psilocybin Treatment
The investment issuer Origin Therapeutics Holdings announced that one of its companies will offer its first psychedelic retreat. The service will be offered by one of its portfolio companies, Dimensions Health Centres Inc. North of Toronto, Dimensions Algonquin Highlands will host group retreats starting this July.